The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
Activate Your Account with an access code or Create a New Account
Michaela Liedtke
Hematologist, Medical oncologist, Multiple myeloma specialist, Leukemia specialist
Assistant Professor of Medicine (Hematology) and, by courtesy, of Pathology at the Stanford University Medical Center
- 875 Blake Wilbur Drive
- Clinic C
- Palo Alto, CA 94304
- Phone: 650-498-6000
- 300 Pasteur Drive
- 2nd Floor, Room A260
- Stanford, CA 94305
- Phone: 650-725-6186
Practice Areas
Professional Education
- Medical Education: Medizinische Hochschule Hannover (1996) Germany
- Fellowship: Memorial Sloan-Kettering Cancer Center (2004) NY
- Board Certification: Medical Oncology, American Board of Internal Medicine (2006)
- Board Certification: Hematology, American Board of Internal Medicine (2005)
- Fellowship: Stanford University Medical Center (2005) CA
- Residency: Albert Einstein College of Medicine (2002) NY
Honors & Awards
- Translational Research Award, Doris Duke Foundation (2004)
- Fellowship Award, Lymphoma Research Foundation (2004)
- Methods in Clinical Cancer Research Scholar, ASCO/AACR (2005)
- Research grant, Hope Street Kids Foundation (2006)
- Young Investigator Award, ASCO (2008)
- Translational Research Award, Stanford Department of Medicine (2011)
Administrative Appointments
- Member, Stanford Amyloid Center (2010 - Present)
- Member Leukemia Committee, Southwest Oncology Group (2011 - Present)
- Medical Director, Stanford Adolescent and Young Adult Program (2015 - Present)
Publications
-
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., & Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British journal of haematology, 173(2), 253-259. -
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., & Kumar, R. (2016). NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. Journal of the National Comprehensive Cancer Network , 14(4), 389-400. -
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
Gertz, M. A., Landau, H., Comenzo, R. L., Seldin, D., Weiss, B., & Liedtke, M. (2016). First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of clinical oncology , 34(10), 1097-1103. -
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., & Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leukemia & lymphoma, 57(3), 609-615.
-
Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature.
Leatham, H. W., Novoa, R., Liedtke, M., & Kwong, B. Y. (2016). Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature. Clinical lymphoma, myeloma & leukemia, 16(1), e1-5.
-
Multiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., & Kumar, R. (2015). Multiple Myeloma, Version 2.2016. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(11), 1398-1435.
-
CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia
Iwasaki, M., Liedtke, M., Gentles, A. J., & Cleary, M. L. (2015). CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. CELL STEM CELL, 17(4), 412-421.
-
Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma
Hansmann, L., Blum, L., Ju, C.-H., Liedtke, M., Robinson, W. H., & Davis, M. M. (2015). Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma. CANCER IMMUNOLOGY RESEARCH, 3(6), 650-660.
-
Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era
Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., & Witteles, R. M. (2015). Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era. AMERICAN JOURNAL OF TRANSPLANTATION, 15(3), 650-658.
-
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., & Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441-1445.
-
Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression
Ohgami, R. S., Sendamarai, A. K., Atwater, S. K., Liedtke, M., Fleming, M. D., & Warnke, R. A. (2014). Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 38(9), 1298-1304.
-
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
Dinner, S., Lee, D., & Liedtke, M. (2014). Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 55(8), 1715-1724.
-
Effects of serum and plasma matrices on multiplex immunoassays
Rosenberg-Hasson, Y., Hansmann, L., Liedtke, M., Herschmann, I., & Maecker, H. T. (2014). Effects of serum and plasma matrices on multiplex immunoassays. IMMUNOLOGIC RESEARCH, 58(2-3), 224-233.
-
Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., & Witteles, R. M. (2014). Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. HEART RHYTHM, 11(1), 158-162.
-
A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia
Patel, S., Liedtke, M., Ngo, D., & Medeiros, B. C. (2013). A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 54(10), 2231-2235.
-
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., & Liedtke, M. (2013). Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. HAEMATOLOGICA, 98(10), 1593-1599.
-
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., & Alhamadsheh, M. M. (2013). AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(24), 9992-9997.
-
The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., & Liedtke, M. (2013). The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(3), 367-372.
-
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., & Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. HAEMATOLOGICA, 98(4), 591-596.
-
Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., & Kumar, R. (2013). Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(1), 11-17.
-
Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21).
-
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., & Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957-960.
-
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., & Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893-901.
-
More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis
Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., & Liedtke, M. (2012). More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 138(5), 509-511.
-
Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2012). Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 31(3), 325-331.
-
Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options.
Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Hematology (Amsterdam, Netherlands).
-
Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., & Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30-37.
-
The Transcription Factor Encyclopedia
Yusuf, D., Butland, S. L., Swanson, M. I., Bolotin, E., Ticoll, A., & Wasserman, W. W. (2012). The Transcription Factor Encyclopedia. GENOME BIOLOGY, 13(3).
-
Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2011). Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy. JOURNAL OF CARDIAC FAILURE, 17(8), S45-S46.
-
A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., & Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347-1347.
-
Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification
Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., & Zehnder, J. L. (2010). Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. BLOOD, 116(21), 1357-1358.
-
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., & Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877-881.
-
Plasma cell leukemia: concepts and management.
Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. Expert review of hematology, 3(5), 543-549.
-
Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6
Liedtke, M., Ayton, P. M., Somervaille, T. Cp., Smith, K. S., & Cleary, M. L. (2010). Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. BLOOD, 116(1), 63-70.
-
Therapeutic targeting of MLL
Liedtke, M., & Cleary, M. L. (2009). Therapeutic targeting of MLL. BLOOD, 113(24), 6061-6068.
-
Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., & Medeiros, B. (2008). Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. LEUKEMIA & LYMPHOMA, 49(3), 581-585.
-
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
Liedtke, M., Hamlin, P. A., Moskowitz, C. H., & Zelenetz, A. D. (2006). Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. ANNALS OF ONCOLOGY, 17(6), 909-913.
-
Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase
Liedtke, M., Pandey, P., Kumar, S., KHARBANDA, S., & Kufe, D. (1998). Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. ONCOGENE, 17(15), 1889-1892.
-
A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV
SELENT, U., RUTER, T., Kohler, E., Liedtke, M., THIELKING, V., & Pingoud, A. (1992). A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV. BIOCHEMISTRY, 31(20), 4808-4815.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, Jul 2016
Dr. Liedtke is wonderful - feel very fantastic to have her as my specialist.
SHC Patient, Jul 2016
All very good.
SHC Patient, Jul 2016
We really love Dr. Liedtke. She is so caring and knowledgeable. We are lucky to have her as a provider. It is hard to find a doctor like her.
SHC Patient, Jun 2016
Outstanding physician for my particular disease.
SHC Patient, Jun 2016
Dr. Liedtke is a great communicator and inspires my confidence in her. I have a lot of questions and she listens and answers them all she is fully responsive to email communications and volunteered her work e-mail address.
SHC Patient, May 2016
Dr. Liedtke, PA, and NP were very knowledgeable. I could ask for any more professional staff to assist me.
SHC Patient, May 2016
I feel so fortunate to have Michaela Liedtke as my myeloma specialist. She answered questions, listens, is informative and caring - truly top notch - could not be in better hands.
SHC Patient, Apr 2016
My experience with the nurses & doctors was great.
SHC Patient, Apr 2016
Excellent doctor always concerned for me.
SHC Patient, Mar 2016
Good.
SHC Patient, Mar 2016
I feel very fortunate and grateful to be cared for by Dr Liedtke
SHC Patient, Mar 2016
I have the utmost confidence in Dr. Liedtke.
SHC Patient, Mar 2016
Nice and very kind.
SHC Patient, Mar 2016
Love everyone at Stanford they are kind and careing and very smart! I would not be alive if I didn't have Stanford to go to that's why I drive four hours to get there!
SHC Patient, Feb 2016
Dr Liedtke has been my doctor for eight years. She is very helpful, understanding, knowledgeable about my disease. My pain, my feelings and knows what treatment I need. She is the same the first time I saw her and until now. I am confident that she can cure me.
SHC Patient, Feb 2016
Excellent! Dr Liedtke is a great communicator. She always understands exactly what I'm asking and gives precise, understandable answers. She has never appeared rushed with me, giving all the time I need to ask questions. She is also very kind.
SHC Patient, Jan 2016
She was an awesome doctor. I was lucky and blessed to have her. She was so kind and considerate. A confident and gentle spirit and a great leader for her staff.
SHC Patient, Jan 2016
I have the highest degree of admiration and respect for Dr. Liedtke.
SHC Patient, Dec 2015
Dr. Liedtke is the best doctor I have ever had. I have seen many, but she by far is the very best. I am very blessed to have her.
SHC Patient, Nov 2015
Dr. Liedtke is very good at responding to messages with questions or concerns I might have between regular appointments. This is all done electronically through the website with no need for phone calls.
SHC Patient, Nov 2015
Fantastic.
SHC Patient, Apr 2015
Thank you Dr Liedtke
SHC Patient, Apr 2015
Always a good experience Dr. Liedtke is very caring and concerned; she always explains my condition in a way I understand. I really like Dr. Liedtke. She's a sweetheart!!!
SHC Patient, Apr 2015
Very pleased with my doctor - Excellent care - Dr. Liedtke.
SHC Patient, Mar 2015
Have been very impressed with Dr. Liedtke in all my dealings with her.
SHC Patient, Jan 2015
Dr. Liedtka listens to you and ask questions. She is understanding of your needs. Being a scrub nurse, I do not do things normally in my medical history. She understands that. She is great.
SHC Patient, Jan 2015
Impressive MD's!
SHC Patient, Jan 2015
No bad experience.
SHC Patient, Dec 2014
Dr. Liedtke is saving my life!
SHC Patient, Oct 2014
Dr. Liedtke had not seen us before, so she was a little surprised, but did a great job.
SHC Patient, Aug 2014
She's a sweetheart - We're very blessed to be in her care.
SHC Patient, Apr 2014
I am very confident with Dr. M Liedtke. Her name is outstanding.
SHC Patient, Jan 2014
Dr. Liedtke is excellent.
SHC Patient, Dec 2013
Good.
SHC Patient, Jul 2016
Dr. Liedtke is wonderful - feel very fantastic to have her as my specialist.
SHC Patient, Jul 2016
All very good.
SHC Patient, Jul 2016
We really love Dr. Liedtke. She is so caring and knowledgeable. We are lucky to have her as a provider. It is hard to find a doctor like her.
SHC Patient, Jun 2016
Outstanding physician for my particular disease.
SHC Patient, Jun 2016
Dr. Liedtke is a great communicator and inspires my confidence in her. I have a lot of questions and she listens and answers them all she is fully responsive to email communications and volunteered her work e-mail address.
SHC Patient, May 2016
Dr. Liedtke, PA, and NP were very knowledgeable. I could ask for any more professional staff to assist me.
SHC Patient, May 2016
I feel so fortunate to have Michaela Liedtke as my myeloma specialist. She answered questions, listens, is informative and caring - truly top notch - could not be in better hands.
SHC Patient, Apr 2016
My experience with the nurses & doctors was great.
SHC Patient, Apr 2016
Excellent doctor always concerned for me.
SHC Patient, Mar 2016
Good.
SHC Patient, Mar 2016
I feel very fortunate and grateful to be cared for by Dr Liedtke
SHC Patient, Mar 2016
I have the utmost confidence in Dr. Liedtke.
View All 34 Patient Comments »